Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
0(0%)
Results Posted
117%(7 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_3
6
86%
Ph phase_2
1
14%

Phase Distribution

0

Early Stage

1

Mid Stage

6

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
1(14.3%)
Phase 3Large-scale testing
6(85.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(6)
Terminated(1)

Detailed Status

Completed6
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
85.7%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (14.3%)
Phase 36 (85.7%)

Trials by Status

terminated114%
completed686%

Recent Activity

0 active trials
Showing 5 of 7
terminatedphase_3

Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria

NCT03219164
completedphase_3

Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

NCT01641822
completedphase_3

Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways

NCT01404234
completedphase_3

Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis

NCT01313624
completedphase_3

Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis

NCT01314716
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT03219164Phase 3

Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria

Terminated
NCT01641822Phase 3

Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

Completed
NCT01404234Phase 3

Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways

Completed
NCT01313624Phase 3

Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis

Completed
NCT01314716Phase 3

Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis

Completed
NCT00805025Phase 2

Evaluation of the Quality of Life Questionnaire-Bronchiectasis (QOL-B) in Patients With Bronchiectasis

Completed
NCT01059565Phase 3

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7